Hematopoietic Retroviral Gene Marking in Patients with Follicular Non-Hodgkin's Lymphoma

References

• McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Odeal P, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 1994; 12: 3
   Web of Science ®Google Scholar
• Solal-Celigny P, Brice P, Brousse N, Caspard H, Bastion Y, Hauion C, Bosly A, Tilly H, Bordessoule D, Sebban C, Harousseau JL, Morel P, Dupas B, Plassart F, Vasile N, Fort N, Leporrier M. Phase II trial of fludarabine monophosphate as first line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe D'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14: 2
   Web of Science ®Google Scholar
• Tefferi A, Witzig TE, Reid JL, Li CY, Ames MM. Phase I study of Combined 2-Chlorodeoxyadenosine and Chlorambucil in Chronic Lymphocytic Leukemia and low grade lymphoma. J Clin Oncol 1994; 12: 3
   Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, Bodkin D, White C, Foon K, Schilder RJ, Neidhart J, Janakiraman N, Waldichuk C, Davis T, Dallaire BK, Royston I, Levy R. IDEC C2B8 Anti-CD20 Antibody: Result of long-term follow-up of relapsed NHL phase II trial patients. Blood 1995; 86(10)54a
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Grillo-Lopez AJ, McLaughlin P, Link BK, Levy R, Czuczman M, Heyman MR, Williams M, Jain V, Bence-Bruckler Ho AD, Lister J, Rogers J, Shen D, Varns C. Anti - CD20 Antibody (MAB), IDEC-C2B8: Clearance of bcl-2 t(14:18) positive cells from peripheral blood and bone marrow in patients with relapsed low-grade or follicular lymphoma. Blood 1996; 88(10)91a
   Web of Science ®Google Scholar
• Freedman AS, Ritz J, Neuberg D, Anderson KC, Rabinowe SN, Mauch P, Takvorian T, Soiffer R, Blake K, Yeap B, Coral F, Helfin L, Nadler LM. Autologous bone marrow transplantation in 69 patients with a history of low grade B cell non-Hodgkin's lymphoma. Blood 1991; 77: 2524
   PubMed Web of Science ®Google Scholar
• Rohatiner A, Johnson P, Price C, Arnott SJ, Norton A, Dorey E, Adams K, Whelan J, Matthews J, MacCallum P, Oza A, Lister T. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177
   PubMed Web of Science ®Google Scholar
• Colombat P, Donadio D, Fouillard L, Milpied N, Tilly H, Pico J, Abrgrall H, Coiffier B, Herbrecht T, Philip T. Value of autologous bone marrow transplantation in follicular lymphoma: A France Autogreffe retrospective study of 41 patients. Bone Marrow Transplant 1994; 13: 157
   PubMed Web of Science ®Google Scholar
• Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J, Nadler LM. High dose therapy and autologous bone marrow transplantation in patient with follicular lymphoma during first remission. Blood 1996; 88: 7
   Google Scholar
• Gribben J, Neuberg D, Freedman A, Gimmi C, Pesek K, Barber M, Saporito L, Woo S, Coral F, Spector N, Rabinowe S, Grossbard B, Ritz J, Nadler L. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449
   PubMed Web of Science ®Google Scholar
• Deisseroth AB, Zu Z, Claxton E, Hanania Eg, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson F, Hester J, Korbling M, Durett Moen R, Berenson R, Heimfeld S, Hamer J, Calvert L, Tibbits P, Talpaz M, Kantarjian H, Champlin R, Reading C. Genetic Marking shows that Ph+ cells present in autologous transplants of Chronic Myelogenous Leukemia contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 10
   PubMed Web of Science ®Google Scholar
• Brenner MK, Rill DR, Holloday MS, Heslop HS, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle J. Gene marking to determine whether autologous marrow infusion restores long term hematopoiesis in cancer patients. Lancet 1993; 342: 1134
   PubMed Web of Science ®Google Scholar
• Brenner MK, Rill DR, Moen RC, Holloday MS, Heslop HS, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle J. Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 8
   PubMed Web of Science ®Google Scholar
• Brenner MK, Rill DR, Moen RC, Holloday MS, Heslop HS, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle J. Autologous bone marrow transplant for children with AML in first complete remission: Use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse. Human Gene Therapy 1991; 2: 137
   PubMed Web of Science ®Google Scholar
• Dunbar CE, Cotler FM, O'Shaghnessy JA. Retrovirally marked CD 34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048
   PubMed Web of Science ®Google Scholar
• Lambrechts AC, Hupkes PE, Dorssers LCJ, van't Veer MB. Clinical significance of translocation t(14;18) positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. J Clin Oncol 1994; 12: 1541
   PubMed Web of Science ®Google Scholar
• Price CGA, Meerabux J, Murtagh S, Cotter FE, Rohatiner AZ, Young BD, Lister TA. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Onco 1991; 9: 1527
   PubMed Web of Science ®Google Scholar
• Dolken G, Illerhaus G, Hirt C, Mertelsmann R. BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 1996; 14: 1333
   PubMed Web of Science ®Google Scholar